difference between liraglutide semaglutide and tirzepatide Liraglutide: Uses, Side Effects, Dosages, Cost, More Understanding Liraglutide, Semaglutide, and Tirzepatide

Baseline assessment before initiating Mounjaro should include: Renal function tests (estimated glomerular filtration rate) Serum electrolytes including potassium Review of concurrent medications Assessment of cardiovascular status Ongoing monitoring recommendations include: Routine follow-up : For uncomplicated patients without risk factors, electrolyte monitoring can follow standard diabetes care protocols, typically annually or as clinically indicated Enhanced monitoring : Patients with risk factors (renal impairment, concurrent diuretics, elderly) should have electrolytes checked 1-3 months after initiation and following dose escalations, following local protocols Symptomatic monitoring : Any patient experiencing persistent gastrointestinal symptoms, particularly vomiting or diarrhoea lasting more than 48 hours, should have electrolytes assessed Management strategies for patients on Mounjaro include: Dose titration : Following the recommended gradual dose escalation schedule (starting at 2.5 mg weekly for 4 weeks, then increasing to 5 mg, with further increases in 2.5 mg increments to 10-15 mg as needed) helps minimise gastrointestinal adverse effects Non-pharmacological measures : Eating smaller, more frequent meals and maintaining adequate hydration may help reduce gastrointestinal symptoms Symptomatic treatment : If non-pharmacological measures are insufficient, antiemetics may be considered for persistent nausea, though should be used judiciously with consideration of potential QT interval effects and drug interactions Hydration advice : Patients should be counselled to maintain adequate fluid intake, particularly during the initial treatment period If electrolyte disturbances are identified, management should address the underlying cause

& Pasquali, R

After 52 weeks of once weekly Zepbound (10 or 15 mg) or placebo, participants on Lillys drug experienced a statistically significant and clinically meaningful reduction in apnea or hypopnea events

Avci et al

A 300mcg protocol in the clinical setting might translate to 350-400mcg in practical application to ensure adequate exposure